Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|June 12, 2002

Amersham takes Optison to Europe

Ultrasound contrast agent Optison has been cleared for sale in the European Union. Amersham Health will begin marketing the echocardiography agent this month. The company obtained comarketing rights to the product from Mallinckrodt in

Ultrasound contrast agent Optison has been cleared for sale in the European Union. Amersham Health will begin marketing the echocardiography agent this month. The company obtained comarketing rights to the product from Mallinckrodt in 2000.

Related to this article

Current Perspectives on Integrating AI into Radiology
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.